Corona Remedies Limited IPO – Mainboard
About the Company
Corona Remedies Limited, founded in 1996 and based in Ahmedabad, is a branded pharmaceutical company focused on creating medicines for specific segments like women’s health, heart/diabetes care, pain management, and urology. Think of them as a “specialist doctor” in pharma—instead of making 100 different medicines, they focus deeply on a few therapeutic areas.
They rank among India’s top 30 pharmaceutical companies by domestic sales (₹1,376 crore in FY25). The company is smart about M&A (mergers & acquisitions)—they’ve bought popular medicine brands from giants like Abbott India (Obimet) and GSK (Vinteurin, Thyrocab) and now sell them under the Corona Remedies umbrella. They’ve also received EU GMP certification (European manufacturing approval), opening doors for global exports.
What They Do: Manufacture and sell branded pharmaceutical formulations (medicines) focused on women’s health, cardio-diabetes, pain, and urology.
READ FULL DRHP HERE: |SEBI DRHP CORONA REMEDIES|
IPO Details Table
| Detail | Explanation | Data |
|---|---|---|
| IPO Opening Date | Buy shares from | 8 Dec 2025 |
| IPO Closing Date | Last date to apply | 10 Dec 2025 |
| Price Band | Price range for shares | ₹1,008 – ₹1,062 per share |
| Lot Size | Min. shares to buy | 14 shares (~₹14,868 at upper band) |
| Total Issue Size | Max money raised | ₹655.37 Crore |
| Fresh Issue | New shares, money goes to company | Nil (100% OFS) |
| Offer for Sale (OFS) | Old owners sell shares | ₹655.37 Crore (0.62 Cr shares = 100%) |
| Listing Date | Shares start trading | 15 Dec 2025 (BSE, NSE) |
| Face Value | Company unit value | ₹10 per share |
| Registrar | Share allocation handler | Bigshare Services Pvt Ltd |
| Book Managers | IPO arrangers | JM Financial, IIFL Capital, Kotak Mahindra Capital |
FIND THE LINK TO CHECK THE ALLOTMENT STATUS: IPO Allotment Status - Big Share Online
What Will the IPO Money Be Used For?
Important: This is a 100% Offer for Sale (OFS). This means:
- All ₹655.37 crore goes to existing shareholders (Dr Kirtikumar Mehta family and investors like Sepia Investments, Anchor Partners).
- The company gets ZERO fresh capital from this IPO.
- This is purely a liquidity event for existing owners to sell their stakes.
IPO Timeline
| Event | Date | What Happens |
|---|---|---|
| IPO Opens | 8 Dec 2025 | Start buying shares |
| IPO Closes | 10 Dec 2025 (5 PM) | Last date to buy shares |
| Allotment Date | 11 Dec 2025 | Find out if you got shares |
| Refunds Issued | 12 Dec 2025 | Get money back if not allotted |
| Shares to Demat | 12 Dec 2025 | Shares show in account |
| Listing Date | 15 Dec 2025 | Market trading starts on BSE/NSE |
Business Model & Revenue Structure
How They Make Money:
- Branded Formulations: Selling medicines under popular brand names (Obimet, Thyrocab, Vitneurin, etc.).
- Retail Distribution: Selling through medical shops, chemists across India (~85% of revenue).
- Export: Growing international sales through EU GMP certified facility.
Therapeutic Areas Focus (FY25):
- Women’s Health: ~25% of sales (gynecological products)
- Cardio-Diabetes: ~30% of sales (heart & diabetic medicines)
- Pain Management: ~20% of sales (painkillers, muscle relaxants)
- Urology & Others: ~25% of sales (urinary issues, other products)
Key Financial Metrics
| Metric | FY23 | FY24 | FY25 (9M) | Q2 FY26 (Jun '25) | Trend |
|---|---|---|---|---|---|
| Revenue | ₹884 Cr | ₹1,014.40 Cr | ₹1,202.35 Cr | ₹348.56 Cr (9M annualized ~₹1,386 Cr) | Growing 20%+ annually |
| Net Profit (PAT) | ~₹110 Cr | ~₹133 Cr | ₹173.56 Cr | ₹46.89 Cr (9M, annualized ~₹184.76 Cr) | Profit growing 35%+ |
| EBITDA | ~₹135 Cr | ~₹161 Cr | ₹245.91 Cr | ₹71.79 Cr (9M) | Strong operational profit |
| EBITDA Margin | 15.3% | 15.9% | 20.45% | 20.55% | Margins expanding to 20%+ |
| PAT Margin | 12.4% | 13.1% | 14.4% | 13.45% | Healthy & stable |
| ROE | 18.5% | 21% | 27.50% | — | Excellent shareholder returns |
| ROCE | 28% | 35% | 41.32% | — | Elite-level capital efficiency |
| Debt-to-Equity | 0.12 | 0.10 | 0.10 | — | Virtually debt-free |
Key Points:
- Consistent Growth: Revenue growing 15-20% annually
- Profit Growth: PAT growing 35%+ (much faster than revenue = margin expansion)
- Exceptional Returns: ROE 27.5%, ROCE 41.32% (among best in pharma sector)
- Debt-Free: D/E of 0.10 is very safe
- Strong Margins: 20% EBITDA, 14% PAT margins
Cost of Acquisition – For Promoters
- Promoters: Dr Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, Dipabahen Niravkumar Mehta (founding family).
- Acquisition Cost: Founded in 1996, the company was built from scratch by the Mehta family with minimal capital.
- Current Valuation: ₹6,495 crore market cap at upper IPO price.
- Promoter Gain: Approximately 5,000x+ returns over 30 years (from ₹100+ crore initial investment to ₹6,500 crore company).
Industry Outlook – India’s Pharmaceutical Market
- Market Size: ₹2.5 lakh crore, growing 8-12% annually.
- Branded Generics Boom: Branded pharmaceutical companies (like Corona) are growing 15-20% vs unbranded generics growing 5-8%.
- Export Opportunity: Indian pharma firms with EU GMP approval can export globally—huge growth lever.
Growth & Strengths (“Biggest Tricks”)
- Strategic M&A: They buy popular brands from big pharma companies (Abbott, GSK) at good prices and leverage their distribution to grow them. This is cheaper than developing new drugs.
- Therapeutic Focus: Instead of competing on 100 medicines, they focus deeply on 4 areas (women’s, cardio, pain, urology). Deeper expertise = better market share.
- Debt-Free: With no debt and strong cash generation, they can fund growth without diluting shareholders.
- Margin Expansion: Moving to 20% EBITDA margins (from 15% five years ago) by improving scale and pricing power.
Key Risks & Concerns
| Risk | Why It Matters | Impact |
|---|---|---|
| 100% OFS | No fresh capital for company; existing owners getting exit | Promoters/investors think valuation is peak |
| High Valuation | P/E of 45-50x is premium for pharma (typical is 30-35x) | Stock may fall post-listing if growth disappoints |
| Price Band Premium | GMP of ₹300+ (28% above upper band) is very high | Huge expectations built into listing price |
| Regulatory Risk | Pharma is heavily regulated; approval delays can hurt | Any compliance issues = stock crash |
| Pricing Pressure | Government price controls on medicines possible | Margins can compress if prices are regulated |
| Intense Competition | From Sun Pharma, Cipla, Lupin, and 200+ other pharma firms | Price wars can hurt profitability |
| Key Customer Risk | If major distributors/retailers stop buying = revenue hit | Customer concentration risk exists |
IPO FAQS
What is an IPO?
- An IPO (Initial Public Offering) is when a private company sells its shares to the public for the first time to raise money.
- Example: If a well-known pizza company wants to grow, it can list its shares on the stock exchange so anyone can buy a piece of the company.
How can you apply for an IPO (using Zerodha or Upstox)?
- Make sure you have a Demat account and your bank account is linked.
- Steps:
- Log in to your broker’s app (e.g., Zerodha Kite, Upstox).
- Go to the IPO section.
- Select the company’s IPO you want to apply for.
- Enter how many shares (or ‘lots’) you want and the price you wish to bid.
- Enter your UPI ID, submit your application, and approve the UPI payment request.
How are IPO shares allotted?
- If more people want shares than are available, the company uses a lottery system to decide who gets them.
- If you don’t get shares, your money is simply returned.
What is GMP (Grey Market Premium)?
- GMP shows the extra price people are willing to pay for IPO shares before they officially start trading.
- Example: If IPO price is ₹100 and GMP is ₹20, people are unofficially ready to pay ₹120. It hints at the IPO’s popularity but isn’t a guarantee.
Where to check upcoming IPOs (IPO calendar)?
- Visit popular finance sites like Chittorgarh, IPOWatch, or official exchange websites (NSE, BSE) and look for the “Upcoming IPO” section.
What are IPO listing gains?
- If the share’s price rises on the first trading day, you can make instant profit.
- Example: You buy at ₹150, and it opens at ₹200, you gain ₹50 per share.
How can you make profit from an IPO?
- Quick gains on listing day (if the stock price goes up).
- Long-term: If the company grows, the share price could increase further.
Which IPO is best to buy?
- There is no single best IPO. Check the company’s background, current demand, and GMP, but always research before investing.
- High GMP or popularity doesn’t guarantee profits.
Are IPOs safe?
- IPOs can be profitable but also risky; prices can go up or down sharply.
- Only invest if you are ready for potential losses.
How to check IPO allotment status?
- After the IPO process, check on exchanges (BSE/NSE websites) or the IPO registrar’s site (like K-Fintech, Bigshare,or mufg-intime) by entering your PAN or application number to see if you got shares.
Important Tips for Retail Investors Applying for an IPO
- Use Only Your Own PAN Card:
Avoid using the same PAN card for multiple IPO applications. For example, if you have already applied using your PAN for one IPO, don’t try to apply again with the same PAN under different accounts or through others. - Apply in the Right Category:
Ensure you select the correct investor category (such as Retail Individual Investor) when filling out your application. Applying under a wrong category can lead to rejection or disqualification. - Maintain Sufficient Bank Balance:
Before applying, ensure your bank account linked to the application has enough funds to cover the full bid amount. For instance, if the IPO application requires a payment of ₹15000, make sure your account holds at least that amount. - Use Your Own Bank Account:
Always apply through your own bank account. Using someone else’s account can cause your application to be rejected during the verification process. - Avoid Last-Minute Applications:
Don’t wait until the deadline day or moments before to apply. Last-minute submissions may face technical glitches or processing delays, reducing the chances of success.